Small Pox Treatment, Brincidofovir, Granted Orphan Drug Designation


The FDA has granted Orphan Drug Designation (ODD) to is product, brincidofovir, for the treatment of smallpox, a serious, and often deadly infectious disease.

This morning, Chimerix announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to is product, brincidofovir, for the treatment of smallpox, a serious, and often deadly infectious disease.

“We are very pleased to have received Orphan Drug Designation from the FDA for brincidofovir as a treatment for smallpox,” Chimerix’s president and chief executive officer M Michelle Berrey, MD, MPH, said in a recent statement. “Though declared eradicated in the late 1970s, smallpox, whether natural of synthetic, continues to be a potential global threat in today’s interconnected world.”

Brincidofovir (CMX001) has demonstrated an improvement in survival rates following orthopoxvirus infections in several animal models.

In order to develop the experimental antiviral drug as a medical countermeasure to treat the disease and any potential outbreaks that may spring up due to a bioterror event or even accidental release, Chimerix has been working closely with the Biomedical Advanced Research and Development Authority since 2011. While 1949 recorded the last natural outbreak of virus, the melting Siberian tundra continues to increase the chances of smallpox making a comeback.

The melting tundra rings alarms from experts since they claim the thawed corpses of those who died during the epidemic over 120 years ago may resurface, resulting in a revived outbreak. Rerason for concern is only validated by a team of researchers in Canada who successfully synthesized the horsepox virus, which is a close relative of smallpox. Additional experts in the field warned against the risky nature of experiments of this nature, which could be the possible opening of Pandora’s box when it comes to deadly diseases.

Previously, the FDA accepted SIGA Technologies, Inc’s New Drug Application for an oral formulation of a smallpox medication called tecovirimat (TPOXX), a novel small molecule antiviral therapy preceding this ODD. In addition, the FDA granted priority review to the application, with the target final action date anticipated to be in August 8, 2018.

“We are committed to completing the development program for brincidofovir as a much-needed treatment option for smallpox, in close collaboration with BARDA and FDA,” Dr Berrey said.

Related Videos
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
A Year of RSV Highs and Lows, with Tina Tan, MD
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
© 2024 MJH Life Sciences

All rights reserved.